摘要
转移性尿路上皮癌预后差,患者中位总生存时间约为14个月。长期以来含顺铂的化疗方案是转移性尿路上皮癌的标准一线治疗,但目前仍缺乏预测因子筛选出治疗有效的患者。近年来免疫治疗进展巨大,治疗有效的患者可长久获益,极大地改变了转移性尿路上皮癌的治疗蓝图。此外,基于对尿路上皮癌基因特征的理解,许多潜在的生物标志物及治疗靶点被发现。本文将对这些已经改变或即将改变转移性尿路上皮癌预后的新型免疫治疗和靶向治疗进行综述。
The prognosis of metastatic urothelial carcinoma （mUC） is poor, with a median overall survival of about 14 months. Platinum-based chemotherapy has been standard for first-line treatment of mUC for a long time, but there is still no predictive biomarker to help guide treatment and select patients most likely to derive benefit from these regimen. Recent advances in immunotherapy has changed the landscape of mUC, with significant improvement in overall survival among responsible patients. Moreover, the advent of next-generation sequencing has resulted in both an improved understanding of the fundamental genetic changes that characterize mUC and identification of several potential biomarkers and therapies. Within this review, we summarized these emerging novel immunotherapy and targeted therapy, which may improve or have improved the outcomes of mUC.
作者
鄢谢桥
盛锡楠
YAN Xie-qiao;SHENG Xi-nan(Department of Renal Cancer and Melanoma,Key Laboratory of Carcinogenesis and Translational Research（Ministry of Education）,Peking University Cancer Hospital ＆ Institute,Beijing 100142,China)
出处
《肿瘤综合治疗电子杂志》
2018年第3期14-20,共7页
Journal of Multidisciplinary Cancer Management(Electronic Version)
基金
北京市医管局扬帆计划(ZYLX201603)
北京市科委首都临床特色应用研究(Z161100000516062)
关键词
转移性尿路上皮癌
免疫治疗
靶向治疗
Metastatic urothelial carcinoma
Immunotherapy
Targeted therapy
